Open AccessThe effectiveness of targeted therapy in the treatment of common forms of ovarian cancer
Author(s) -
В. В. Саевец,
Саевец Валерия Владимировна,
А. В. Важенин,
Важенин Андрей Владимирович,
Людмила Федоровна Чернова,
Чернова Людмила Федоровна,
Ирина Григорьевна Шимоткина,
Шимоткина Ирина Григорьевна,
О. В. Курченкова,
Курченкова Ольга Валерьевна,
А. А. Мухин,
Мухин Арсентий Андреевич,
А. В. Таратонов,
Таратонов Алексей Владимирович
Publication year - 2018
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/18151434.2018.4.180176
Subject(s) - medicine , bevacizumab , carboplatin , ovarian cancer , surgery , hysterectomy , stage (stratigraphy) , confidence interval , paclitaxel , oncology , cancer , chemotherapy , paleontology , cisplatin , biology
Purpose of the study. To evaluate the effectiveness of the targeted drug bevacizumab (Avegra®) in the complex treatment of patients with common forms of ovarian cancer after suboptimal cytoreductive surgical interventions. Materials and methods. For the period from January 2017 to November 2018. A clinical study included and treated 71 patients with a diagnosis of ovarian cancer, stage IIIC-IV disease. The prevalence of the tumor process was estimated according to the classification of FIGO and TNM (2009). Patients were randomized into two groups. The first group included 31 patients, the treatment was carried out according to the scheme: paclitaxel 175 mg/m2, carboplatin AUC 6, bevacizumab 15 mg/kg with an interval of 21 days. The second group (control group) included 40 patients who received standard drug therapy. Interval suboptimal cytoreductive surgery was performed in all patients - hysterectomy with appendages, epiploic resection, peritonectomy. Evaluation of the effectiveness of immediate and remote The results were carried out by the method of statistical processing using the program Statistic 6.0. Results. According to the criteria of RESIST 1.1 in the first group, a complete response was registered in 25.8%, a partial response in 51.6%, stabilization of the disease in 12.9%, progression of 9.6% of cases. In the second group, the complete response was in 20% of cases, a partial response was 45%, stabilization was 22.5%, progression was 12.5%. The median overall survival in the first group was 16.5 months аgainst 10.1 months in the second group.